Previous 10 | Next 10 |
Merck & Co. is a large legacy company that makes a profit, pays a consistent dividend, and is a familiar and dependable company. That sometimes makes for boring. Analysts have a consensus target price in the mid-$90s while it might be undervalued by over 50%. Merck develops an...
Alkermes (ALKS) has entered into a clinical trial collaboration and supply agreement with Merck (MRK) for a planned phase 3 study to evaluate nemvaleukin alfa in combination with blockbuster cancer drug Keytruda, in comparison to investigator choice chemotherapy in patients wit...
Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer PR Newswire DUBLIN , April 7, 2021 /PRNewswire/ -- Alkermes plc (N...
Alkermes to Take Part in Stifel's 3rd Annual CNS Day PR Newswire DUBLIN , March 25, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3 rd Annual CNS Day on Thurs...
At Investor Day, Alkermes ([[ALKS]] +2.3%) has outlined its growth strategy for 2023 and 2024 targeting 25% and 30% of non-GAAP net income margin for the years, respectively.That compares with ~7.0% margin estimated for 2021 on the mid-point of revenue guidance at $1.1 – 1.2B...
Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy - Company Will Provide New Updates and Disclose New Programs in Neuroscience and Oncology Development Pipeline- - Updated Nemvaleukin Clinical Response Data from ARTISTRY-1 and ARTISTRY-2 Studi...
Biopharma company Alkermes (ALKS), which was targeted by activist investor Elliott Management last year, may face further pressure from another activist fund Sarissa Capital Management.Sarissa, led by Alex Denner, who at one time worked for Carl Icahn, is the biggest hedge fund owner of Alker...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors head into next week with plenty of wildcards to size up, including U.S. trade relations with China, the Treasu...
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma PR Newswire DUBLIN , March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred ...
Alkermes (ALKS) receives FDA orphan designation for its fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha in the treatment of mucosal melanoma.Among the benefits of Orphan Drug status in the U.S. is a seven-year period ...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...